Publication:
Acquired progressive lymphangioma: Case report with partial response to imiquimod 5% cream

dc.contributor.authorSALMAN, ANDAÇ
dc.contributor.authorYÜCELTEN, AYŞE DENİZ
dc.contributor.authorSARAÇ ÖZTÜRK, GONCA
dc.contributor.authorERGUN, SAFİYE ATLAS TÜLİN
dc.contributor.authorCİNEL, ZELİHA LEYLA
dc.contributor.authorsSalman, Andac; Sarac, Gonca; Kuru, Burce Can; Cinel, Leyla; Yucelten, Ayse Deniz; Ergun, Tulin
dc.date.accessioned2022-03-12T22:23:40Z
dc.date.accessioned2026-01-11T06:49:27Z
dc.date.available2022-03-12T22:23:40Z
dc.date.issued2017
dc.description.abstractAcquired progressive lymphangioma (APL), or benign lymphangioendothelioma, is an unusual entity derived from vascular structures. Clinically and histopathologically it may resemble Kaposi's sarcoma and well-differentiated angiosarcoma, causing a diagnostic problem. We report an individual with APL initially diagnosed with Kaposi's sarcoma who underwent unnecessary laboratory testing. Imiquimod 5% cream stopped the progression of the lesion. Awareness of this rare entity may prevent patients from undergoing excessive testing. Imiquimod may be used as a safe, effective treatment option.
dc.identifier.doi10.1111/pde.13283
dc.identifier.eissn1525-1470
dc.identifier.issn0736-8046
dc.identifier.pubmed28940760
dc.identifier.urihttps://hdl.handle.net/11424/234506
dc.identifier.wosWOS:000415350800003
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofPEDIATRIC DERMATOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectdermatopathology
dc.subjecthemangiomas
dc.subjectvascular tumors
dc.subjecttopical therapy
dc.titleAcquired progressive lymphangioma: Case report with partial response to imiquimod 5% cream
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPageE304
oaire.citation.issue6
oaire.citation.startPageE302
oaire.citation.titlePEDIATRIC DERMATOLOGY
oaire.citation.volume34

Files